Maxim Group Upgrades CNS Pharmasceuticals Inc. (CNSP) to Buy, 'Berubicin Glioblastoma Data is Coming into View'

Maxim Group analyst Jason McCarthy upgraded CNS Pharmasceuticals Inc. (NASDAQ: CNSP) from Hold to Buy with a price target of $0.50.

The analyst comments "Overall, our fundamental and positive views on Berubicin and its opportunity in GBM have remained unchanged; it was the capital constraints that pushed the CNS story essentially to the brink. Management, over the past few years, has done a remarkable job, in our view, navigating the company through its most challenging period, which was compounded by both challenging biotech markets and a difficult financing environment in general. Now, with cash on the balance sheet and runway to the data, we believe the risk/reward profie is favorable."

For an analyst ratings summary and ratings history on CNS Pharmasceuticals Inc. click here. For more ratings news on CNS Pharmasceuticals Inc. click here.

Shares of CNS Pharmasceuticals Inc. closed at $0.14 yesterday.

You May Also Be Interested In

• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• New Street Research Upgrades Micron Technology (MU) to Buy
• Wolfe Research Upgrades Abbvie (ABBV) to Outperform